V8 Peptides — Engineered Performance
Research Library
GLP-1 Peptides Compared: Receptors and Assay Choice
IncretinsMechanism

GLP-1 Peptides Compared: Receptors and Assay Choice

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How do semaglutide, tirzepatide, retatrutide and cagrilintide differ for research design? They differ by receptor. Semaglutide engages the GLP-1 receptor, tirzepatide the GIP and GLP-1 receptors, and retatrutide the GIP, GLP-1 and glucagon receptors, all Gs-coupled class B receptors. Cagrilintide belongs to a different system: the calcitonin receptor and its RAMP-dependent amylin receptor complexes. A valid comparison therefore needs a single-receptor cell line for each target, the native ligand as reference, a null line, and HPLC-checked stocks. All four are for laboratory research use only.

Searches for a GLP-1 peptide comparison usually end at a list of names. Researchers planning an experiment need something else: a map from compound to receptor, and from receptor to assay. This article is built that way. It handles semaglutide, tirzepatide, retatrutide and cagrilintide as four tools with different targets, then works through the assay and control decisions that follow. It deliberately does not rank them or say anything about outcomes in people; all four are laboratory research materials, supplied for laboratory research use only and not for human consumption. For a side-by-side overview of the four compounds with product context, the 2026 four-compound comparison covers that ground; this piece is about design choices.

Start with the receptor, not the compound

The four compounds fall into two different mechanistic families.

CompoundReceptors engagedReceptor familyMain signaling readout in cells
------------
SemaglutideGLP-1 receptorClass B GPCR (incretin)cAMP accumulation via Gs
TirzepatideGIP receptor and GLP-1 receptorClass B GPCR (incretin)cAMP via Gs at both receptors
RetatrutideGIP, GLP-1 and glucagon receptorsClass B GPCRcAMP via Gs at three receptors
CagrilintideCalcitonin receptor and amylin receptor complexesClass B GPCR with RAMP partnerscAMP via Gs, dependent on RAMP expression

The first three are incretin-family agonists with progressively broader receptor coverage; the published pharmacology for tirzepatide (Coskun et al., 2018) and retatrutide (Coskun et al., 2022) describes how each receptor was characterized in cell-based assays and how potency at each receptor was compared. Semaglutide's design, a GLP-1 analog with a fatty-acid side chain for albumin binding, is described by Lau and colleagues (2015). Cagrilintide is the outlier. It belongs to the amylin axis, a separate hormone system whose receptors are assembled from the calcitonin receptor and one of three receptor-activity-modifying proteins (RAMPs), as described by Hay and colleagues and in the foundational work by Christopoulos et al. (1999) and Poyner et al. (2002).

That distinction is the single most useful thing to carry into design. An experiment in a cell line that expresses the GLP-1 receptor tells you nothing about cagrilintide, and an experiment in a line that has the calcitonin receptor but no RAMP expression may show a very different profile from one with RAMP coexpression.

Matching the assay to the receptor

Cell systems

A clean receptor assay starts with a defined system. Recombinant cell lines expressing a single human receptor give an unambiguous readout and allow potency comparison across compounds. For triple agonists the lab needs three lines, one per receptor, each with a verified expression level, because potency measured in a high-expression line looks better than the same compound in a low-expression line. For cagrilintide the system must express the calcitonin receptor together with a RAMP; coexpressing RAMP1, RAMP2 or RAMP3 gives the AMY1, AMY2 and AMY3 subtypes respectively, and the response differs with the partner. Native cells such as pancreatic islet preparations contain several receptors at once and are better for integrated questions than for pharmacological ones.

Readouts

Gs-coupled receptors raise intracellular cAMP, which can be read with a reporter-gene assay, a FRET or luminescence biosensor, or an immunoassay on lysate. Beta-arrestin recruitment and receptor internalization add a second dimension that the cAMP signal alone cannot show. Because acylated peptides bind albumin, the medium matters: the apparent potency of a lipidated compound falls when serum albumin is present, so the assay buffer should be stated with the result and kept constant when comparing compounds.

Comparators

Every comparison should include the native agonist for the receptor as a reference: GLP-1(7-36), GIP(1-42), glucagon, and amylin or calcitonin for the amylin axis. Expressing results as a ratio to the native ligand in the same plate removes much of the plate-to-plate variation.

Which control answers which question

Control design is where comparison experiments usually fail. The following table lists the questions that appear most often and the control that answers each.

QuestionControl that answers itCommon mistake
---------
Is the response receptor-mediated?Parental cell line lacking the receptor; selective antagonistReporting a signal without a null cell line
Is potency at one receptor affected by the others?Single-receptor lines, one at a timeUsing one mixed line and attributing the signal
Is a difference caused by the acyl chain?An unacylated analog or a different albumin conditionComparing compounds in different serum levels
Is the compound intact?HPLC and mass check of the stock before useAssuming vial label equals tested concentration
Is the stock concentration correct?Quantification by amino acid analysis or HPLC against a standardUsing nominal mass divided by volume as measured

The last two rows are handled before any biology starts. Understanding HPLC purity and how to read a COA are the starting points for the identity side, and the reconstitution calculator handles the nominal arithmetic: concentration equals vial mass divided by diluent volume.

Cross-compound design problems

Fixed-ratio comparisons

When two compounds are compared at the same molar concentration, convert from mass using each compound's own molecular weight. These molecules differ greatly in size, so equal milligrams per milliliter are not equal molar amounts. The mismatch is largest between a short analog and a large acylated molecule. The molecular formula shown for cagrilintide on its product page can be used for the calculation.

Combination experiments

Studies that pair an incretin agonist with an amylin analog need two separate dose-response curves and a combination matrix, because adding the effects of two curves is not the same as testing an interaction. A published example of the rationale for pairing the two axes is outlined in the cagrilintide and semaglutide combination background. A checkerboard design, with each compound varied across its range, lets an analysis separate additive behavior from interaction.

Species

Receptor pharmacology varies across species. A compound's potency at the rat receptor can differ from that at the human receptor, and rodent amylin differs from human amylin in its propensity to aggregate. State the species of every receptor, and avoid mixing species in one comparison without noting it. Cagrilintide's characterization in rodents is discussed in the preclinical rodent literature overview.

Handling differences that affect the comparison

All four are acylated or otherwise delicate peptides, but their handling is not identical. Large lipidated peptides adsorb to plastic and foam when agitated; the amylin analog also carries a disulfide ring that reducing agents will open. Tirzepatide, semaglutide and retatrutide have no ring to protect but carry their own sensitivities. Keep lyophilized stock cold and dry, record the storage history, and avoid repeated freeze–thaw cycles on any of them; the general principles are in storing research peptides. The V8 product pages for retatrutide and cagrilintide give the supplied sizes and storage lines.

A minimal comparison design

A reasonable first experiment compares the four compounds, each against its native reference, in a set of defined single-receptor lines plus a null line. Each compound is run as a full concentration curve in the same buffer. Stocks are checked by HPLC before use. The result is a potency matrix, one row per compound and one column per receptor, with the native ligand as the 1.0 reference in each column. Reading across a row shows selectivity; reading down a column shows relative potency at one receptor. That matrix, not a ranking, is the useful output.

Limits of what a comparison can say

In vitro potency does not predict behavior in a whole animal. Binding affinity, signaling bias, albumin binding, metabolic clearance and tissue distribution all contribute to what is seen in an animal model, and receptor-expression patterns differ among tissues. Any statement about effect size outside the assay should be left to the primary literature and kept out of a methods summary. The GLP-1 receptor agonists in research page and incretin receptors explained give the background on the receptor side.

Frequently asked questions

Which receptors do semaglutide, tirzepatide, retatrutide and cagrilintide act on?

Semaglutide acts on the GLP-1 receptor, tirzepatide on the GIP and GLP-1 receptors, and retatrutide on the GIP, GLP-1 and glucagon receptors. Cagrilintide acts on the calcitonin receptor and the amylin receptors formed with RAMP proteins.

Is cagrilintide a GLP-1 receptor agonist?

No. It is an amylin analog and acts on the amylin and calcitonin receptor system, which is separate from the incretin receptors. It is often studied next to GLP-1 agonists, but the targets differ.

What is the best cell line for comparing these compounds?

There is no single best line. A defined single-receptor line for each target gives interpretable potency values, plus a parental line lacking the receptor as a null control. Amylin-receptor work needs coexpression of the calcitonin receptor and a RAMP.

Why does serum albumin change potency results for these peptides?

Acylated peptides bind albumin, which lowers the free concentration available to the receptor. The apparent potency of a lipidated compound therefore shifts with the albumin level in the assay buffer, so the buffer must be reported and held constant.

Can mg/mL concentrations be compared between compounds?

Not for pharmacology. Equal mass concentrations are not equal molar concentrations because the molecules differ in size. Convert to molar using each compound's molecular weight before comparing potency.

Why use the native ligand as a reference in each plate?

Reporting a result as a ratio to GLP-1, GIP, glucagon or amylin measured on the same plate removes much of the variation between plates and between cell batches.

Does in vitro potency predict results in animals?

Only partly. Albumin binding, clearance, tissue distribution and receptor expression all affect animal studies. A potency matrix describes the receptor interaction, not whole-organism outcomes.

How should combination experiments with an incretin analog and an amylin analog be designed?

Run each compound as its own concentration curve and add a checkerboard in which both are varied. That design separates additive behavior from true interaction, which two separate curves cannot do.

Where can the supplied forms of the V8 compounds be checked?

On the individual product pages, which list sizes, purity as measured by HPLC, form and storage; certificates of analysis are linked where published.

Related reading: Incretin and Amylin Research Peptides Compared (2026).

References

  1. Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
  2. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009
  3. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013
  4. Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183-11194. doi:10.1021/acs.jmedchem.1c00565
  5. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD, Poyner DR. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. 2015;67(3):564-600. doi:10.1124/pr.115.010629
  6. Christopoulos G, Perry KJ, Morfis M, et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol. 1999;56(1):235-242. doi:10.1124/mol.56.1.235
  7. Poyner DR, Sexton PM, Marshall I, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002;54(2):233-246. doi:10.1124/pr.54.2.233

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.